DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,653,129 B2 Fein Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,653,129 B2 Fein Et Al USOO8653129B2 (12) United States Patent (10) Patent No.: US 8,653,129 B2 Fein et al. (45) Date of Patent: Feb. 18, 2014 (54) COMBINATION THERAPY FORSKN (52) U.S. Cl. DSORDERS USPC ............ 514/457; 514/619; 549/406:564/163 (58) Field of Classification Search (75) Inventors: Howard Fein, Rolling Hills Estates, CA USPC .................... 514/457, 619; 549/406:564/163 (US); Mindy B. Berlin, Delray Beach, See application file for complete search history. FL (US) (73) Assignee: M. Alphabet 1, LLC, Deerfield Beach, (56) References Cited FL (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 2007/0225301 A1 9, 2007 Weidner patent is extended or adjusted under 35 2010/0076O71 A1 3/2010 Lephart U.S.C. 154(b) by 0 days. FOREIGN PATENT DOCUMENTS Appl. No.: 13/518,818 (21) WO WO 2005.10777O A1 * 11, 2005 (22) PCT Filed: Apr. 11, 2011 WO WO 2010/038234 4/2010 OTHER PUBLICATIONS (86) PCT NO.: PCT/US2O11AO31886 Bu et al., Reproductive Biology and Endocrinology, 2005, BioMed S371 (c)(1), Central, vol. 3, pp. 1-8.* (2), (4) Date: Jun. 22, 2012 Yang et al., Journal of Natural Products, 2001, American Chemical Society, vol. 64, pp. 313-317.* (87) PCT Pub. No.: WO2O11A149595 Indian Journal of Dermatology, Venereology, & Leprology, 2009, PCT Pub. Date: Dec. 1, 2011 Medknow Publ., vol. 75, supplement 1, pp. S44-S46.* Tanaka et al., Letters in Applied Microbiology, 2002. The Society for Prior Publication Data Applied Microbiology, vol. 35, pp. 494-498.* (65) Webster, British Medical Journal, 2002, British Medical Association, US 2012/O283225A1 Nov. 8, 2012 vol. 325, pp. 475-479.* Related U.S. Application Data * cited by examiner (60) Provisional application No. 61/349.240, filed on May 28, 2010, provisional application No. 61/369,391, Primary Examiner — Sarah Pihonak filed on Jul. 30, 2010. (74) Attorney, Agent, or Firm — Duane Morris, LLP; Lee Crews (51) Int. C. AOIN 43/16 (2006.01) (57) ABSTRACT A6 IK3I/35 (2006.01) AOIN37/18 (2006.01) The present invention provides a novel therapeutic combina A6 IK3I/65 (2006.01) tion comprising one or more anti-androgen agents and one or CO7D 3II/00 (2006.01) more antibiotic/anti-inflammatory agents or pharmaceuti CD7C233/00 (2006.01) cally acceptable salts or hydrates thereof, useful for the treat C07C 235/00 (2006.01) ment of a dermatological disorder. C07C 237/00 (2006.01) C07C 239/00 (2006.01) 12 Claims, No Drawings US 8,653,129 B2 1. 2 COMBINATION THERAPY FORSKN maceutically acceptable salts or hydrates thereof, useful for DISORDERS the treatment of a dermatological disorder Such as acne. The therapy combination of the present invention provides a syn FIELD OF THE INVENTION ergistic effect in treating a Subject with a dermatological disorder. The present invention also provides a method for treating The present invention is directed to a therapy comprising a or preventing a dermatological disorder by administering a novel combination of one or more anti-androgen agents and pharmaceutical composition comprising one or more anti one or more antibiotic/anti-inflammatory agents or pharma androgen agents and one or more antibiotic/anti-inflamma ceutically acceptable salts or hydrates thereof, useful for the tory agents or pharmaceutically acceptable salts or hydrates treatment of a dermatological disorder Such as acne. 10 thereof. BACKGROUND OF THE INVENTION DETAILED DESCRIPTION OF THE INVENTION Acne is a disorder of the pilosebaceous glands located on This invention provides novel pharmaceutical composi the face, chest and back. It is an almost universal disease, 15 tions comprising one or more anti-androgen agents and one or occurring in all races, predominantly among adolescents. The more antibiotic/anti-inflammatory agents as a combination of pathogenesis of acne is multi-factorial involving increased separate active agents oras a combined composition compris sebum production by the sebaceous glands. Such as caused by ing both active agents. Such compositions are useful for Sup increased activity of sebocytes, sometimes via peroxisome pressing, inhibiting, preventing, alleviating or treating a der proliferator-activated receptor ligands; ductal hypercomifica matological disorder, including, but not limited to, acne tion of the pilosebaceous unit of the dermis and epidermis and Vulgaris, telogen effluvium, androgenetic alopecia, and acne hyperkeratinization (increased activity of keratinocytes); OSaCCa. inflammation; and the presence of the anaerobic bacteria The combination of the present invention can be adminis Propionibacterium acnes (P. acnes). tered at any time and in any effective form. The anti-androgen The American Academy of Dermatology has reported that 25 agent and the antibiotic/anti-inflammatory agent may be 85% to 100% of those aged 12-24 are affected by either administered simultaneously, e.g., as a single combination or intermittent or persistent acne, which in a number of adoles dosage unit (e.g., a pill or liquid containing both composi cents results in scarring attributed to acne (Bershad, The tions), or they may be administered as separate compositions, Mount Sinai Journal of Medicine, Vol. 68, p. 279-286, 2001; but at the same time (e.g., where one drug is administered White, Journal of American Academy of Dermatology, Vol. 30 intravenously and the other is administered orally or intra 39, p. S34-37, 1998). Furthermore, acne can remain problem muscularly). The anti-androgen agent and the antibiotic/anti atic into the third to fifth decades of life, particularly in inflammatory agent may also be administered sequentially at women. Tan et al., (Journal of American Academy of Derma different times. tology, Vol. 44 (Supplement 3), p. 439-445, 2001), has It is understood that the anti-androgen agents and antibi reported that approximately 3% of all male adults and 12% of 35 otic/anti-inflammatory agents of the present invention all female adults in the U.S. suffer from acne. include all analogs, isomers, metabolites, derivatives, phar There is no cure for acne. Many medications are available maceutically acceptable salts, N-oxides, hydrates or any for treating acne including topical retinoids (i.e., adapalene, combination thereof. tazarotene, tretinoin), antimicrobial and antibacterial agents Anti-Androgen Agents: (i.e., benzoyl peroxide, clindamycin, erythromycin, sodium 40 Examples of general anti-androgen agents used singly or in sulfacetamide with or without sulfur), oral antibiotics (i.e., combination in the present invention are, but not limited to, doxycycline, minocycline, tetracycline, azithromycin, trime oral contraceptives, estrogen analogs, progesterone analogs, thoprim-sulfamethoxazole (TMP/SMX), that primarily spironolactone, inocoterone acetate, cyproterone acetate, reduces the population of P. acnes, hormonal agents as anti flutamide, nilutamide, bicalutamide, ketoconazole, finas androgens (i.e., oral contraceptives) that decrease sebum 45 teride, dutasteride, bexlosteride, izonsteride, epresteride, secretion, Systemic retinoids (i.e., isotretinoin), and topical turosteride, an isoflavanoid, RU-58642, RU-56279, WS9761 aminolevulinic acid plus blue light (also known as photody A and B, RU-59063, RU-58841, bexlosteride, LG-2293, namic theory). L-245976, LG-121071, LG-121091, LG-121104, LGD Various agents administered in acne treatments exhibit 2226, LGD-2941, YM-92088, YM-175735, LGD-1331, director indirect antibiotic activity but also directly suppress 50 LGD-3303, BMS-357597, S-0503, BMS-482404, EM-4283, inflammation by decreasing neutrophil chemotaxis and EM-4977, BMS-564929, BMS-391197, BMS-434588, down-regulate the expression of pro-inflammatory media BMS-487745, BMS-501949, SA-766, YM-92088, YM-580, tors. Oral antibiotics are indicated for several groups of LG-123303, LG-123129, PMCol, YM-175735, BMS patients with inflammatory acne. They include tetracyclines 591305, BMS-591309, BMS-665139, BMS-665539, CE (i.e., tetracycline, doxycycline, minocycline, erythromycin, 55 590, 116BG33, 154BG31, arcarine, ACP-105, flutamide, clindamycin, and cotrimoxazole). hydroxyflutamide, bicalutamide, nilutarnide, hydroxysteroid With the high incidence of acne and other dermatological dehydrogenase inhibitors, PPARC. ligands such as bezafi disorders that are of a major clinical health concern to both brate, fenofibrate, gemfibrozil; PPARY ligands such as dargli males and females, new innovative approaches are urgently taZone, pioglitaZone, rosiglitaZone, isaglitaZone, rivoglita needed at both the basic science and clinical levels to decrease 60 Zone, netoglitaZone; dual acting PPAR ligands, such as the incidence of dermatological disorders. naVeglitazar, fargilitazar, tesaglitazar, ragaglitazar, Oxegli tazar, PN-2034, PPAR 8: 17-ketoreductase inhibitors, SUMMARY OF THE INVENTION 3f-DHA4.6-isomerase inhibitors, 3B-DHA4.5-isomerase inhibitors, 17.20 desmolase inhibitors, p450c17 inhibitors, The present invention provides a novel pharmaceutical 65 p450ssc inhibitors, and 17.20-lyase inhibitors, or mixtures composition comprising one or more anti-androgen agents thereof. The most preferred anti-androgen agents used in the and one or more antibiotic/anti-inflammatory agents or phar present invention are spironolactone and an isoflavanoid. US 8,653,129 B2 3 4 Isoflavanoids (as illustrated below by the left-hand struc exhibit polymorphism. It is to be understood that the present ture) or isoflavonoids (as illustrated below by the right-hand invention encompasses any racemic, optically active, diaste structure) that may be used in the present invention
Load more

Recommended publications
  • World Journal of Pharmaceutical Research Sonam Et Al
    World Journal of Pharmaceutical Research Sonam et al . World Journal of Pharmaceutical SJIF ImpactResearch Factor 5.990 Volume 4, Issue 8, 2393-2402. Review Article ISSN 2277– 7105 5-α-REDUCTASE INHIBITORS - A REVIEW Sonam Kaushal* and Manish Sinha Department of Pharmaceutical Chemistry, ASBASJSM College, Bela, Ropar, India. ABSTRACT Article Received on 19 June 2015, 5-alpha reductase is an important enzyme in metabolic pathway of Revised on 10 July 2015, testosterone. Its three subtypes SRD5A1, SRD5A2 andSRD5A3 are Accepted on 02 Aug 2015 responsible for conversion of testosterone to its more potent derivative dihydrotestosterone (DHT). Excess production of DHT leads to *Correspondence prostate cancer and alopecia. The production of DTH can be reduced For Author by inhibiting the 5-alpha reductase enzyme. Several 5-alpha reductase Sonam Kaushal Department of inhibitors were synthesized in the past and are marketed and used for Pharmaceutical the treatment of prostate cancer and baldness. The dosing of these Chemistry, ASBASJSM drugs is between 1 to 5 mg/day. The low dosing of these drugs need College, Bela, Ropar, special attention on quality control and quantitative estimation of drug India. in formulation and biological fluids. The details of 5-alpha reductase inhibitors and the recent developments in their quantitative estimation have been compiled in the presented review. KEYWORDS: 5-α-reductae inhibitors, cancer, quantitative estimation. 1. INTRODUCTION 1. 5-α-Reductase[1, 2, 3] 1.1. 5-α-reductases, also known as 3-oxo-5α-steroid 4-dehydrogenases, are enzymes involved in steroid metabolism. They participate in 3 metabolic pathways: bile acid biosynthesis, androgen and estrogen metabolism.
    [Show full text]
  • Study Protocol: LPCN 1021-18-001
    Oral Testosterone Undecanoate Protocol No. LPCN 1021-18-001 Lipocine Inc. TU, LPCN 1021 675 Arapeen Drive, Suite 202 Salt Lake City, UT-84108 1.0 TITLE PAGE Clinical Study Protocol: LPCN 1021-18-001 Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men. Investigational Product : Testosterone Undecanoate (TU, LPCN 1021) Date of Protocol : 19 February 2019 FDA IND No. : 106476 Development Phase : Phase 3 Testosterone replacement therapy in adult, 18 years or older, males for conditions associated with a deficiency or absence of endogenous Indication : testosterone – primary hypogonadism (congenital or acquired) or secondary hypogonadism (congenital or acquired) Investigator : Multi-Center, US Sponsor : Lipocine Inc. 675 Arapeen Drive, Suite 202, Salt Lake City, Utah – 84108 Tel: +1-801-994-7383 Fax: +1-801-994-7388 Sponsor / : Nachiappan Chidambaram Emergency Contact 675 Arapeen Drive, Suite 202, Salt Lake City, Utah – 84108 Tel: +1-801-994-7383, Ext 2188 Fax: +1-801-994-7388 Email: [email protected] Protocol Version : 06 Confidentiality Statement This document is a confidential communication of Lipocine Inc. Acceptance of this document signifies agreement by the recipient that no unpublished information contained within will be published or disclosed to a third party without prior written approval, except that this document may be disclosed to an Institutional Review Board under the same conditions of confidentiality. Date: 19 February 2019 Confidential Page 1 of 50 Oral Testosterone Undecanoate Protocol No. LPCN 1021-18-001 Lipocine Inc. TU, LPCN 1021 675 Arapeen Drive, Suite 202 Salt Lake City, UT-84108 2.0 SUMMARY OF CHANGES TO PROTOCOL VERSION 2 Version 02 of the LPCN 1021-18-001 study protocol was developed to make the following changes to the study: • Added sexual desire and sexual distress questions to pre-treatment and post-treatment phases of the study.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • General Agreement on Tariffs Andtrade
    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
    [Show full text]
  • Control of the Formation and the Action of Androgens in Peripherai, Tissues
    Cailin Chen Docteur en Médecine Hunan Medical University CONTROL OF THE FORMATION AND THE ACTION OF ANDROGENS IN PERIPHERAI, TISSUES These présentée B la Faculté des études supérieures de 11Universit4Laval pour l'obtention du grade de Philosophiae Doctor (PhD.) Départment de Physiologie (Endocrinologie moléculaire) FACULTÉ DE MÉDECINE UNIVERSITÉ LAVAL QUÉBEC MAI 1996 8 Cailin Chen, 1996 Biblioth ue naaionale du Cana"ei a Acquisitions and Acquisitions et Bibliographie Services services bibliographiques 395 Wellington Street 395. me Wellington MEawaON KlA ON4 OrtewaOkl KtAON4 Caneda Canada The author has granted a non- L'auteur a accordé une licence non exclusive licence ailowing the exclusive permettant a la National Library of Canada to Bibhotheque nationale du Canada de reproduce, loan, distn'bute or seii reproduire, prêter, distribuer ou copies of this thesis in microfonn, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/fdm, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fiom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. To: Xun, Chenchen, and My parents L'andtoghe actif 5a-dihydrotestost6rone (Dm joue un r61e prédominant tan physiologique important dans la peau et la prostate. Afin de mieux comprendrd les mécanismes impliqués dans la formation et l'action de la Dïïï, nous avon 4tu&4 la distribution tissulaire de certaines enzymes de la stéroïdogénèse chez 1r hamster et nous avons démontré la psesence des enzymes nécessaires h li biosynthbe de la DHT dans tous les tissus stdroidogéniques et une series dr tissus périphériques.
    [Show full text]
  • Topical Cyproterone Acetate Treatment in Women with Acne a Placebo-Controlled Trial
    STUDY Topical Cyproterone Acetate Treatment in Women With Acne A Placebo-Controlled Trial Doris M. Gruber, MD; Michael O. Sator, MD; Elmar A. Joura, MD; Eva Maria Kokoschka, MD; Georg Heinze, MSc; Johannes C. Huber, MD, PhD Objective: To evaluate the clinical and hormonal re- Results: After 3 months of therapy with topical cypro- sponse of topically applied cyproterone acetate, oral cy- terone acetate, the decrease of mean facial acne grade from proterone acetate, and placebo lotion in women with 1.57 to 0.67 was significantly better (P<.05) compared with acne. placebo (which showed a change from 1.57 to 1.25), but not compared with oral medication (1.56 to 0.75) (P >.05). Design: Placebo-controlled, randomized study. Lesion counts also decreased from 35.9 to 9.1 in the topi- cal cyproterone acetate group compared with oral medi- Setting: Patients were recruited from the Institute of En- cation (45.4 to 15.5) (P..05) and placebo (38.2 to 23.1) docrine Cosmetics, Vienna, Austria. (P,.05). After topical cyproterone acetate treatment, se- rum cyproterone acetate concentrations were 10 times lower Patients: Forty women with acne. than those found after oral cyproterone acetate intake. Interventions: Treatment with oral medication con- Conclusions: The therapeutic effect of topically ap- sisting of 0.035 mg of ethinyl estradiol and 2 mg of cy- plied cyproterone acetate for acne treatment was clearly proterone acetate (n=12), 20 mg of topical cyproterone demonstrated. Topically applied sexual steroids in com- acetate lotion (n=12), and placebo lotion (n=16) was of- bination with liposomes are as effective as oral antian- fered.
    [Show full text]
  • Cha Kuna Taiteit Un Certain Et Annet Inn
    CHA KUNA TAITEIT US009925232B2UN CERTAIN ET ANNET INN TIN (12 ) United States Patent (10 ) Patent No. : US 9 , 925 , 232 B2 Fein et al. (45 ) Date of Patent: Mar. 27, 2018 ( 54 ) METHODS AND COMPOSITIONS 4 ,505 ,616 A 3 / 1985 Grzelka et al . COMPRISING DESMOPRESSIN IN 4 , 557 , 934 A 12 / 1985 Cooper 4 ,783 ,450 A 11/ 1988 Fawzi et al. COMBINATION WITH A 5 - ALPHA 5 ,023 ,252 A 6 / 1991 Hseih REDUCTASE INHIBITOR 5 ,534 ,496 A 7 / 1996 Lee et al. 6 , 558, 695 B2 5 /2003 Luo et al . (71 ) Applicant: Serenity Pharmaceuticals LLC , 7 , 112 , 561 B2 9 / 2006 Gyurik et al. 7 , 182, 747 B2 2 / 2007 Kwon Milford , PA (US ) 7 ,244 , 703 B2 7 /2007 Gyurik et al. 7 , 335 ,186 B2 2 / 2008 O 'Neil @(72 ) Inventors : Seymour H . Fein , New Canaan , CT 7 , 405 , 203 B2 7 / 2008 Fein (US ) ; Linda Cheng , West Nyack , NY NNNN7 , 579 , 321 B2 8 / 2009 Fein (US ) ; Maria Cheng , Chestnut Ridge , 7 , 799 , 761 B2 9 / 2010 Fein NY (US ) ; Samuel Herschkowitz , 8 , 143 , 225 B2 3 / 2012 Fein 8 , 399 , 410 B2 3 / 2013 Herschkowitz et al. Brooklyn , NY (US ) 9 , 375 , 530 B2 6 /2016 Herschkowitz et al . 9 , 539 ,302 B2 1 / 2017 Fein @(73 ) Assignee : Serenity Pharmaceuticals , LLC , 2004 / 0138098 A1 * 7 / 2004 Fein . 514 / 2 Milford , PA (US ) 2009 /0042970 A1 * 2 / 2009 Herschkowitz et al . .. .. 514 / 423 2010 /0056436 A 3 / 2010 Fein 2010 /0160214 AL 6 /2010 Fein et al . ( * ) Notice : Subject to any disclaimer , the term of this 2012 / 0015880 A11 / 2012 Fein patent is extended or adjusted under 35 2012 /0149643 A1 * 6 /2012 Fein .
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Pairwise Comparisons
    National Institute for Health and Care Excellence Final Acne vulgaris: management [E2] Management options for mild to moderate acne – pairwise comparisons NG198 Evidence review underpinning recommendations 1.5.1, 1.5.2 and 1.5.5 to 1.5.14 (excluding 1.5.6 which is underpinned by evidence review L, 1.5.10 and bullet points 2 and 3 of recommendation 1.5.12 which are underpinned by evidence review F1 and 3 research recommendations in the NICE guideline - see evidence review E1 for the committee’s discussion of the evidence) June 2021 Final These evidence reviews were developed by the National Guideline Alliance which is a part of the Royal College of Obstetricians and Gynaecologists FINAL Error! No text of specified style in document. Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
    [Show full text]